Today The Schaper Benz & Wise Investment Counsel Inc. WI Has $6,186,000 Position in IDEXX Laboratories, Inc. (IDXX)

Today The Schaper Benz & Wise Investment Counsel Inc. WI Has $6,186,000 Position in IDEXX Laboratories, Inc. (IDXX)

Schaper Benz & Wise Investment Counsel Inc. WI decreased its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 1.3% during the third quarter, Holdings Channel reports. The fund owned 54,875 shares of the company’s stock after selling 700 shares during the period. Schaper Benz & Wise Investment Counsel Inc. WI’s holdings in IDEXX Laboratories were worth $6,186,000 as of its most recent filing with the SEC.

Several other large investors have also recently bought and sold shares of IDXX. Vanguard Group Inc. raised its stake in IDEXX Laboratories by 3.8% in the second quarter. Vanguard Group Inc. now owns 6,703,403 shares of the company’s stock valued at $622,478,000 after buying an additional 242,670 shares during the last quarter. Fundsmith LLP raised its stake in IDEXX Laboratories by 6.1% in the second quarter. Fundsmith LLP now owns 4,469,336 shares of the company’s stock valued at $415,023,000 after buying an additional 258,657 shares during the last quarter. BlackRock Fund Advisors raised its stake in IDEXX Laboratories by 7.1% in the second quarter. BlackRock Fund Advisors now owns 3,545,865 shares of the company’s stock valued at $329,269,000 after buying an additional 236,526 shares during the last quarter. BlackRock Institutional Trust Company N.A. raised its stake in IDEXX Laboratories by 24.9% in the second quarter. BlackRock Institutional Trust Company N.A. now owns 3,268,627 shares of the company’s stock valued at $303,525,000 after buying an additional 651,138 shares during the last quarter. Finally, State Street Corp raised its stake in IDEXX Laboratories by 18.0% in the second quarter. State Street Corp now owns 2,770,661 shares of the company’s stock valued at $257,287,000 after buying an additional 422,021 shares during the last quarter. 90.75% of the stock is currently owned by institutional investors and hedge funds.

IDEXX Laboratories, Inc. (NASDAQ:IDXX) traded up 1.37% during mid-day trading on Wednesday, reaching $120.13. 56,993 shares of the company’s stock were exchanged. The stock has a market capitalization of $10.77 billion, a PE ratio of 51.16 and a beta of 0.51. IDEXX Laboratories, Inc. has a 1-year low of $63.48 and a 1-year high of $121.81. The firm’s 50-day moving average is $118.92 and its 200 day moving average is $111.32.

IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings data on Tuesday, November 1st. The company reported $0.62 EPS for the quarter, beating analysts’ consensus estimates of $0.60 by $0.02. The company had revenue of $448.30 million for the quarter, compared to analyst estimates of $448.60 million. IDEXX Laboratories had a net margin of 12.36% and a negative return on equity of 788.91%. IDEXX Laboratories’s quarterly revenue was up 10.3% on a year-over-year basis. During the same period in the previous year, the business posted $0.48 earnings per share. Analysts forecast that IDEXX Laboratories, Inc. will post $2.38 earnings per share for the current fiscal year.

A number of research analysts recently weighed in on IDXX shares. Bank of America Corporation reaffirmed a “neutral” rating on shares of IDEXX Laboratories in a research note on Thursday, September 29th. Zacks Investment Research lowered shares of IDEXX Laboratories from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, October 4th. Finally, Canaccord Genuity set a $125.00 price target on shares of IDEXX Laboratories and gave the company a “buy” rating in a research note on Saturday, October 15th. One analyst has rated the stock with a sell rating, four have assigned a hold rating and five have issued a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average price target of $105.20.

In other news, Director William T. End sold 5,000 shares of the business’s stock in a transaction dated Tuesday, November 8th. The shares were sold at an average price of $109.87, for a total transaction of $549,350.00. Following the transaction, the director now directly owns 48,654 shares in the company, valued at $5,345,614.98. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Thomas Craig sold 8,500 shares of the business’s stock in a transaction dated Wednesday, November 23rd. The stock was sold at an average price of $120.06, for a total transaction of $1,020,510.00. Following the transaction, the director now owns 32,783 shares in the company, valued at $3,935,926.98. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 94,112 shares of company stock worth $10,745,322. 2.79% of the stock is currently owned by company insiders.

About IDEXX Laboratories

Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX).

Related posts

Leave a Comment